|Day Low/High||66.50 / 67.69|
|52 Wk Low/High||60.32 / 82.72|
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis...
It's behavioral finance at its finest, and makes for a fascinating debate.
The biotech company reports downside bottom-line results, though it beats on revenue.
Medicine is a slow business and I view Gilead Sciences as a hold for now.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 11% in the company's quarterly cash dividend, beginning in the first quarter of 2019.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2018.
Seagate, Hartford Financial and Gilead are set to report after the bell Monday.
And why maintaining a small position in defense stocks is important.
U.S. stock futures rise modestly as investors focus on stronger-than-expected jobs and manufacturing data from the United States last week; Google parent Alphabet reports earnings Monday after the closing bell; Donald Trump says there's a 'good chance' of a trade deal with China; the New England Patriots win their sixth Super Bowl title.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes.
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg), a once-daily treatment for adults with chronic hepatitis C virus (HCV) infection...
Gilead Sciences, Inc. (NASDAQ: GILD) and Yuhan Corporation (000100.
And it is happening not a moment too soon.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that members of the executive management team will participate in a fireside chat at the 37 th Annual J.
-- Agenus Webcast and Conference Call Scheduled for Today at 8:30a.m.ET --
Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc.
Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta...
Stocks finished the day higher on Monday as gains by tech stocks offset concerns over the fate of U.S.-China trade talks, and after the U.K. delayed a parliamentary vote on Brexit.
Daniel O'Day will take over the helm of the biopharmaceutical giant on March 1, 2019.
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
U.S. stock futures turn mixed as investors continue to express concerns over the fate of U.S.-China trade talks; Tesla's Elon Musk says, 'I do not respect the SEC'; Carlos Ghosn and Nissan are indicted in Japan for underreporting the former chairman's pay.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel O'Day Chairman of the Board and Chief Executive Officer, effective March 1, 2019.
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the National Medical Products Administration (NMPA) has approved Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) in China for the treatment of chronic hepatitis C virus (HCV) genotype 1-6 infection...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the China National Medical Products Administration (NMPA) has approved Descovy ® (emtricitabine 200 mg/tenofovir alafenamide 10 mg and emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a...
Kite, a Gilead Company (Nasdaq: GILD), announced updated results from ZUMA-3, a single-arm Phase 1/2 study evaluating KTE-X19 (formerly KTE-C19), an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy, in adult patients with relapsed or...
Kite, a Gilead Company (Nasdaq: GILD), announced two-year efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta ® (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.